|
07.09.2017 11:49:07
|
New Drugs Approved In August
(RTTNews) - The bench to bedside journey of drugs is no easy task. Some drug candidates fail to complete the journey while many make it to the finish line only after undergoing numerous obstacles.
So far this year, 31 novel drugs have already received FDA approval whereas for the full year of 2016, just 22 novel drugs were approved. Novel drugs are new molecular entities (NMEs) having chemical structures that have never been approved before.
Let's take a look at the new drugs approved in August 2017, including novel drugs.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Pfizer Inc.mehr Nachrichten
Analysen zu Pfizer Inc.mehr Analysen
| 14.11.24 | Pfizer Neutral | UBS AG | |
| 01.11.24 | Pfizer Neutral | UBS AG | |
| 30.10.24 | Pfizer Buy | Goldman Sachs Group Inc. | |
| 29.10.24 | Pfizer Buy | Jefferies & Company Inc. | |
| 24.10.24 | Pfizer Neutral | JP Morgan Chase & Co. |
Aktien in diesem Artikel
| AbbVie Inc | 169,48 | 3,33% |
|
| Agios Pharmaceuticals Inc | 53,50 | 0,94% |
|
| Ironwood Pharmaceuticals Inc (A) | 3,28 | 2,50% |
|
| Jazz Pharmaceuticals PLC | 120,95 | 1,90% |
|
| Kamada Ltd | 5,87 | 0,34% |
|
| Novartis AG (Spons. ADRS) | 99,60 | 2,05% |
|
| Pfizer Inc. | 24,55 | 2,85% |
|
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.